Shots:

• The clinical data from the P-I first-in-human single ascending dose study evaluating RLYB116 (SC) in healthy patients, showed a reduction in free C5 ≤99% at 24hrs. for 100mg dose and at 12, 24, and 72hrs. for 300mg dose, well-tolerated with mild to mod. AEs and no drug-related serious AEs were seen
• Mean estimated elimination half-life for RLYB116 was >300hrs. The P-I multiple ascending dose study of RLYB116 is ongoing while the preliminary safety, PK & PD data are expected in Q4’23
• The company has 2 clinical-stage programs i.e., RLYB212, an anti-HPA-1a Ab for the prevention of fetal & neonatal alloimmune thrombocytopenia, and RLYB116, a C5 inhibitor indicated to treat several diseases of complement dysregulation, as well as additional programs in preclinical development

Ref: Businesswire | Image: AbCellera

Related News:- AbCellera Collaborated with Rallybio to Develop and Commercialize Novel Antibody-Based Therapies for the Treatment of Rare Diseases